Protocol for Development of Evidence-Based Guidelines for Diagnosis and Treatment of Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis among Children in China (2023 Edition)
Xiong Huaying, Yu Xinyi, Mao Jianhua, et al. Protocol for Development of Evidence-Based Guidelines for Diagnosis and Treatment of Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis among Children in China (2023 Edition)[J]. 2022,28(11):1-4.
Xiong Huaying, Yu Xinyi, Mao Jianhua, et al. Protocol for Development of Evidence-Based Guidelines for Diagnosis and Treatment of Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis among Children in China (2023 Edition)[J]. 2022,28(11):1-4. DOI: 10.13407/j.cnki.jpp.1672-108X.2022.11.001.
In order to standardize the diagnosis and treatment of antineutrophil cytoplasmic antibody-associated glomerulonephritis (AAGN) among children
improve the prognosis of children with AAGN
the National Clinical Research Center for Child Health and Disorders (Children’s Hospital of Chongqing Medical University) collaborate with the Nephrology Group of Pediatrics Society of Chinese Medical Association to develop Protocol for Development of Evidence-Based Guidelines for Diagnosis and Treatment of Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis among Children in China (2023 Edition). The Guideline Development Committee will be based on available literature evidence on children
and in accordance with the principles of evidence-based guideline development
a multidisciplinary team of experts including nephrology
immunity
clinical laboratory and imaging fields has been formed to carry out the guideline development work. This protocol mainly introduces the significance and purpose of the guideline